It is proposed to develop plasmids which express antisense RNA and to apply these plasmids to model systems and human tumor cell lines in order to determine the function and intervene in the expression of selected oncogenes. The c-fos and c-sis proto-oncogenes have been is chosen for analysis. Autocrine stimulation by the c-sis product, PDGF-II, has been implicated as a cause of transformation in several human tumor types including osteosarcoma, fibrosarcoma and glioblastoma. Further, PDGF is a potent fibroblast mitogen and stimulator of the c-fos gene which appears to act as a necessary intermediate in the recruitment of quiescent fibroblasts into the cell cycle. An activated c-fos gene has been shown to transform primary cells and the viral transduced forms cause murine osteosarcomas and avian nephroblastomas. It is proposed that the c-fos gene may be activated in and contribute to the properties of the phenotype of v-sis transformed cells. In model studies using a continuously expressing antisense c-fos RNA plasmid in v-sis transformed cells it has been observed that the cellular fos gene is indeed activated and that antisense-mediated subtraction of c-fos mRNA leads to restoration of contact inhibition. A systematic study is now proposed to extend these studies in order to confirm the mechanism of antisense c-fos RNA and to extend the application to cells transformed by the v-fos gene (RS-2 cells). Further we propose to develop a range of improved plasmids and to extend the approach to human tumor lines known to exhibit autocrine stimulation by PDGF-like molecules. Conditional plasmids directing the expression of sense and antisense sis RNA have already been obtained and a prototype of the proposed extended range of antisense c-fos RNA expressing plasmids has been prepared. Thus all the essential methods and materials to complete the proposals are available. In summary, experiments are designed to test whether the c-sis and/or c-fos genes function in certain human tumors and whether the antisense technique is a valid means of analysis and intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA049963-03
Application #
3194332
Study Section
Pathology B Study Section (PTHB)
Project Start
1989-06-23
Project End
1994-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Huang, R P; Fan, Y; de Belle, I et al. (1997) Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72:102-9
Huang, R P; Fan, Y; Ni, Z et al. (1997) Reciprocal modulation between Sp1 and Egr-1. J Cell Biochem 66:489-99
Gjerset, R A; Fakhrai, H; Shawler, D L et al. (1995) Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway. In Vitro Cell Dev Biol Anim 31:207-14
Huang, R P; Liu, C; Fan, Y et al. (1995) Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 55:5054-62
Huang, R P; Darland, T; Okamura, D et al. (1994) Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. Oncogene 9:1367-77
Mercola, D; Carpenter, P M; Grover-Bardwick, A et al. (1992) Rapid, complete and reversible transformation by v-sis precedes irreversible transformation. Oncogene 7:1793-803
Carpenter, P M; Mercola, M; Mercola, D (1991) Reversible transformation by v-sis: a model cell line for analysis of transformation by antisense methods. Antisense Res Dev 1:289-95
Ragona, G; Edwards, S A; Mercola, D A et al. (1991) The transcriptional factor Egr-1 is synthesized by baculovirus-infected insect cells in an active, DNA-binding form. DNA Cell Biol 10:61-6
Wu, J X; Carpenter, P M; Gresens, C et al. (1990) The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5:989-1000